H
Hidefumi Higashi
Researcher at Memorial Hospital of South Bend
Publications - 91
Citations - 2531
Hidefumi Higashi is an academic researcher from Memorial Hospital of South Bend. The author has contributed to research in topics: Hepatectomy & Varices. The author has an hindex of 25, co-authored 90 publications receiving 2409 citations. Previous affiliations of Hidefumi Higashi include Kyushu University & University of Pittsburgh.
Papers
More filters
Journal Article
Influence of blood transfusion on postoperative long-term liver function in patients with hepatocellular carcinoma.
Hidetoshi Itasaka,Kazuharu Yamamoto,Akinobu Taketomi,Hidefumi Higashi,Tatsuro Kamakura,Takashi Matsumata +5 more
TL;DR: The influence of blood transfusion in the patients with hepatocellular carcinoma was considered to be minimum within 2 years after hepatectomy, and liver function tests at one and two years after the surgery showed no significant difference between the two groups.
Journal ArticleDOI
Localized biphasic type malignant mesothelioma arising in the peritoneum: Report of a case
Mikihiro Kohno,Riichiroh Maruyama,Dai Kitagawa,Keishi Sugimachi,Mitsuru Kinjo,Hidefumi Higashi +5 more
TL;DR: A 69‐year‐old male with a history of asbestos exposure, complaining of a painful mass in the left chest wall, was found via computed tomography to have a tumor in theleft peritoneum that was histologically and immunohistochemically consistent with a malignant mesothelioma.
Journal ArticleDOI
Physical assessment immediately after lobectomy via miniposterolateral thoracotomy assisted by videothoracoscopy for non-small cell lung cancer.
Riichiroh Maruyama,Junko Tanaka,Dai Kitagawa,Ryuji Ohta,Kouta Yamauchi,Hitoshi Ayabe,Hirofumi Shimazoe,Hidefumi Higashi,Yoshihiko Maehara +8 more
TL;DR: The advantages of VAmPLT lobectomy over PLT include less postoperative pain and earlier recovery of physical function.
Journal ArticleDOI
Sterility of bile in multiple-organ donors
TL;DR: A bacteriologic study was undertook to see if flushing of the biliary system introduced a potential source of contamination of other organs.
Journal ArticleDOI
Phase II trial of an alternating regimen consisting of first-line mFOLFOX6 plus bevacizumab and FOLFIRI plus bevacizumab for patients with metastatic colorectal cancer: FIREFOX plus bevacizumab trial (KSCC0801).
Keisuke Miwa,Eiji Oki,Yasunori Emi,Hiroshi Saeki,Tetsuya Kusumoto,Yoshito Akagi,Yutaka Ogata,Hironori Samura,Shoji Tokunaga,Hiroshi Ishikawa,Takaho Tanaka,Susumu Sueyoshi,Hidefumi Higashi,Hiroyuki Matsuda,Tetsuo Touyama,Yoshihiko Maehara +15 more
TL;DR: An alternating regimen consisting of mFOLFOX6 plus bevacizumab and FOLFIRI plus beVacIZumab is an effective and well-tolerated first-line chemotherapy combination for patients with metastatic colorectal cancer.